Table 3.
ncRNA’s involved in drug resistance of lung cancer.
| ncRNA | Exosome Origin | Drug | Reference |
|---|---|---|---|
| miR-100-5p | A549 | Cisplatin | [158] |
| H19 | HCC827, HCC4006 | Gefitinib | [159] |
| H19 | Serum, HCC827, A549 | Erlotinib | [160] |
| RP11-838N2.4 | HCC827, HCC4006 | Erlotinib | [161] |
| miR-425-3p | A549 | Cisplatin | [162] |
| MSTRG.292666.16 | Plasma, H1975 | Osimertinib | [163] |
| UCA1 | HCC827, PC9 | Geftinib | [164] |
| FOXD3-AS1 | A549 | 5-fluorouracil | [165] |
| AGAP2-AS1 | A549, H460 and H1299 | Radioresistance | [166] |
| cicHIPK3 cicPTK2 |
A549 | Pexidartinib | [167] |
| cic0014235 | Non-small cell lung cancer | Cisplatin | [168] |
| miR-96 | H1299 | Cisplatin | [169] |
| miR-222-3p | A549-GR | Gemcitabine | [170] |